Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
2.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy535. [Epub ahead of print] No abstract available.

PMID:
30624662
3.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy531. [Epub ahead of print] No abstract available.

PMID:
30624581
4.

Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.

Hurvitz SA, O'Shaughnessy J, Mason G, Yardley D, Jahanzeb M, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M.

Clin Cancer Res. 2018 Dec 28. pii: clincanres.2366.2018. doi: 10.1158/1078-0432.CCR-18-2366. [Epub ahead of print]

PMID:
30593513
5.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.

Di Leo A, O'Shaughnessy J, Sledge GW Jr, Martin M, Lin Y, Frenzel M, Hardebeck MC, Smith IC, Llombart-Cussac A, Goetz MP, Johnston S.

NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.

6.

One-year parasitological screening of stray dogs and cats in County Dublin, Ireland.

Garcia-Campos A, Power C, O'Shaughnessy J, Browne C, Lawlor A, McCarthy G, O'Neill EJ, de Waal T.

Parasitology. 2018 Dec 18:1-7. doi: 10.1017/S0031182018002020. [Epub ahead of print]

PMID:
30561289
7.

Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2018 Nov 26. doi: 10.1093/annonc/mdy517. [Epub ahead of print]

PMID:
30475950
8.

French-Canadian adaptation and validation of the Swiss Spinal Stenosis Questionnaire for patients with lumbar spinal stenosis.

Marchand AA, Tétreau C, OʼShaughnessy J, Descarreaux M.

Spine (Phila Pa 1976). 2018 Oct 11. doi: 10.1097/BRS.0000000000002896. [Epub ahead of print]

PMID:
30312270
9.

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.

Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A.

Mol Cancer Ther. 2019 Jan;18(1):204-212. doi: 10.1158/1535-7163.MCT-18-0243. Epub 2018 Oct 10.

PMID:
30305342
10.

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.

BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.

11.

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.

Wilson TR, Udyavar AR, Chang CW, Spoerke JM, Aimi J, Savage HM, Daemen A, O'Shaughnessy JA, Bourgon R, Lackner MR.

Mol Cancer Res. 2019 Jan;17(1):97-108. doi: 10.1158/1541-7786.MCR-18-0619. Epub 2018 Aug 31.

PMID:
30171174
12.

Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.

O'Shaughnessy J, Thaddeus Beck J, Royce M.

Cancer Treat Rev. 2018 Sep;69:204-214. doi: 10.1016/j.ctrv.2018.07.013. Epub 2018 Jul 23. Review.

13.

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.

Wu TC, Xu K, Martinek J, Young RR, Banchereau R, George J, Turner J, Kim KI, Zurawski S, Wang X, Blankenship D, Brookes HM, Marches F, Obermoser G, Lavecchio E, Levin MK, Bae S, Chung CH, Smith JL, Cepika AM, Oxley KL, Snipes GJ, Banchereau J, Pascual V, O'Shaughnessy J, Palucka AK.

Cancer Res. 2018 Sep 15;78(18):5243-5258. doi: 10.1158/0008-5472.CAN-18-0413. Epub 2018 Jul 16.

PMID:
30012670
14.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.

15.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.

PMID:
29718092
16.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS.

Breast Cancer Res Treat. 2018 Aug;170(3):547-557. doi: 10.1007/s10549-018-4770-6. Epub 2018 Apr 19.

PMID:
29675680
17.

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.

Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W.

Breast Cancer Res Treat. 2018 Aug;170(3):535-545. doi: 10.1007/s10549-018-4769-z. Epub 2018 Apr 13.

18.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Jul 15;24(14):3348-3357. doi: 10.1158/1078-0432.CCR-17-3059. Epub 2018 Apr 4.

PMID:
29618616
19.

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J.

Cancer Med. 2018 Jun;7(6):2288-2298. doi: 10.1002/cam4.1472. Epub 2018 Mar 26.

20.

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.

Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.

PMID:
29501363
21.

Validation of the French-Canadian Pelvic Girdle Questionnaire.

Girard MP, O'Shaughnessy J, Doucet C, Lardon E, Stuge B, Ruchat SM, Descarreaux M.

J Manipulative Physiol Ther. 2018 Mar - Apr;41(3):234-241. doi: 10.1016/j.jmpt.2018.01.001. Epub 2018 Feb 15.

PMID:
29456093
22.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

PMID:
29373071
23.

Cytotechnologists as coinvestigators in anatomical pathology research.

Kopp KJ, Passow MR, Del Rosario KM, Christensen MR, O'Shaughnessy JW, Bartholet MK, Francis ME, Flotte TJ.

Cancer Cytopathol. 2018 Apr;126(4):232-235. doi: 10.1002/cncy.21968. Epub 2018 Jan 9.

PMID:
29316317
24.

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.

Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Parulekar WR, Liedke PER, Chen BE, Goss PE.

Eur J Cancer. 2018 Feb;90:19-25. doi: 10.1016/j.ejca.2017.11.014. Epub 2017 Dec 20.

PMID:
29274617
25.

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A.

Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.

PMID:
29236940
26.

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.

Miles D, Cameron D, Hilton M, Garcia J, O'Shaughnessy J.

Eur J Cancer. 2018 Feb;90:153-155. doi: 10.1016/j.ejca.2017.10.018. Epub 2017 Nov 23. No abstract available.

PMID:
29174181
27.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.

Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.

28.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.

O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.

Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17.

29.

Understanding cardiopulmonary resuscitation.

Masters BJ, Mandeir J, O'Shaughnessy J, Sundar S.

J Pediatr. 2017 Nov;190:291-292. doi: 10.1016/j.jpeds.2017.07.031. No abstract available.

PMID:
29144260
30.

Epidemiological investigation of a severe rumen fluke outbreak on an Irish dairy farm.

O'Shaughnessy J, Garcia-Campos A, McAloon CG, Fagan S, de Waal T, McElroy M, Casey M, Good B, Mulcahy G, Fagan J, Murphy D, Zintl A.

Parasitology. 2018 Jun;145(7):948-952. doi: 10.1017/S0031182017002086. Epub 2017 Nov 16.

PMID:
29143720
31.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

32.

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Nov;166(1):327-328. doi: 10.1007/s10549-017-4482-3. No abstract available.

PMID:
28884461
33.

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.

Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O'Shaughnessy J.

Clin Breast Cancer. 2018 Feb;18(1):e89-e95. doi: 10.1016/j.clbc.2017.07.002. Epub 2017 Jul 10.

34.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

35.

Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials.

Shapley S, O'Shaughnessy J, Woodcock J.

Ther Innov Regul Sci. 2017 Jul;51(4):416-418. doi: 10.1177/2168479017701801. Epub 2017 Apr 16.

PMID:
30227045
36.

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2017 Nov;166(1):327-328.

37.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5485.

38.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

39.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

40.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

41.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

42.

The mechanism of back pain relief by spinal manipulation relies on decreased temporal summation of pain.

Randoll C, Gagnon-Normandin V, Tessier J, Bois S, Rustamov N, O'Shaughnessy J, Descarreaux M, Piché M.

Neuroscience. 2017 May 4;349:220-228. doi: 10.1016/j.neuroscience.2017.03.006. Epub 2017 Mar 11.

PMID:
28288900
43.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J.

J Clin Oncol. 2017 Apr 1;35(10):1041-1048. doi: 10.1200/JCO.2016.69.2871. Epub 2017 Jan 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):359.

PMID:
28113032
44.
45.

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.

Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J.

ESMO Open. 2016 Aug 22;1(4):e000072. eCollection 2016.

46.

Current Practices in Lumbar Surgery Perioperative Rehabilitation: A Scoping Review.

Marchand AA, O'Shaughnessy J, Châtillon CÉ, Sorra K, Descarreaux M.

J Manipulative Physiol Ther. 2016 Nov - Dec;39(9):668-692. doi: 10.1016/j.jmpt.2016.08.003. Epub 2016 Nov 9. Review.

PMID:
27838141
47.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, Masuda N, Ro J, Denduluri N, Hubeaux S, Quah C, Bais C, O'Shaughnessy J.

Eur J Cancer. 2017 Jan;70:146-155. doi: 10.1016/j.ejca.2016.09.024. Epub 2016 Nov 4.

PMID:
27817944
48.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S.

Ann Oncol. 2017 Feb 1;28(2):313-320. doi: 10.1093/annonc/mdw562.

PMID:
27803006
49.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Dec 27;379(26):2582.

50.

The hedgehog pathway in triple-negative breast cancer.

Habib JG, O'Shaughnessy JA.

Cancer Med. 2016 Oct;5(10):2989-3006. doi: 10.1002/cam4.833. Epub 2016 Aug 18. Review.

Supplemental Content

Loading ...
Support Center